<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Antifungals: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i288.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i288.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i288.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i287.htm" title="Previous: Vigabatrin">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1125.htm" title="Next: Micafungin">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i288">Antifungals</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Antifungals</b>
          has no specific interaction information.
        </p><p><b>Micafungin</b> belongs to
      <b>Antifungals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i290.htm">Amphotericin</a></td><td> micafungin possibly increases plasma concentration of amphotericin </td><td>Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td> micafungin possibly increases plasma concentration of ciclosporin </td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td> micafungin increases plasma concentration of itraconazole (consider reducing dose of itraconazole)</td><td></td></tr><tr><td><a href="41001i475.htm">Nifedipine</a></td><td> micafungin increases plasma concentration of nifedipine </td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td> micafungin increases plasma concentration of sirolimus </td><td></td></tr></tbody></table><p><b>Caspofungin</b> belongs to
      <b>Antifungals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>








<tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  caspofungin possibly reduced by carbamazepine—consider increasing dose of caspofungin</td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>plasma concentration of  caspofungin increased by ciclosporin (manufacturer of caspofungin recommends monitoring liver enzymes)</b></td><td></td></tr><tr><td><a href="41001i490.htm">Dexamethasone</a></td><td>plasma concentration of  caspofungin possibly reduced by dexamethasone—consider increasing dose of caspofungin</td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  caspofungin possibly reduced by efavirenz—consider increasing dose of caspofungin</td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td>plasma concentration of  caspofungin possibly reduced by nevirapine—consider increasing dose of caspofungin</td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  caspofungin possibly reduced by phenytoin—consider increasing dose of caspofungin</td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  caspofungin initially increased and then reduced by rifampicin (consider increasing dose of caspofungin)</td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> caspofungin reduces plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr></tbody></table><p><b>Antifungals, Polyene</b> belongs to
      <b>Antifungals</b>
          but has no specific interaction information.
        </p><p><b>Amphotericin</b> belongs to
      <b>Antifungals</b>
          and has the following interaction information:
        </p><div>Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>















<tr><td><a href="41001i128.htm">Aminoglycosides</a></td><td>increased risk of nephrotoxicity when  amphotericin given with aminoglycosides </td><td></td></tr><tr><td><a href="41001i293.htm">Antifungals, Imidazole</a></td><td>effects of  amphotericin possibly antagonised by imidazoles </td><td></td></tr><tr><td><a href="41001i300.htm">Antifungals, Triazole</a></td><td>effects of  amphotericin possibly antagonised by triazoles </td><td></td></tr><tr><td><a href="41001i1168.htm">Arsenic Trioxide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amphotericin given with arsenic trioxide </b></td><td></td></tr><tr><td><a href="41001i478.htm">Cardiac Glycosides</a></td><td class="cBV"><b>hypokalaemia caused by  amphotericin increases cardiac toxicity with cardiac glycosides </b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  amphotericin given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i484.htm">Corticosteroids</a></td><td class="cBV"><b>increased risk of hypokalaemia when  amphotericin given with corticosteroids—avoid concomitant use unless corticosteroids needed to control reactions</b></td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i539.htm">Diuretics, Loop</a></td><td>increased risk of hypokalaemia when  amphotericin given with loop diuretics </td><td></td></tr><tr><td><a href="41001i525.htm">Diuretics, Thiazide and related</a></td><td>increased risk of hypokalaemia when  amphotericin given with thiazides and related diuretics </td><td></td></tr><tr><td><a href="41001i820.htm">Flucytosine</a></td><td> amphotericin reduces renal excretion and increases cellular uptake of flucytosine (toxicity possibly increased)</td><td></td></tr><tr><td><a href="41001i1125.htm">Micafungin</a></td><td>plasma concentration of  amphotericin possibly increased by micafungin </td><td></td></tr><tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td>possible increased risk of nephrotoxicity when  amphotericin given with pentamidine isetionate </td><td></td></tr><tr><td><a href="41001i189.htm">Polymyxins</a></td><td>increased risk of nephrotoxicity when  amphotericin given with polymyxins </td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  amphotericin given with tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i218.htm">Vancomycin</a></td><td>possible increased risk of nephrotoxicity when  amphotericin given with vancomycin </td><td></td></tr></tbody></table><p><b>Flucytosine</b> belongs to
      <b>Antifungals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i290.htm">Amphotericin</a></td><td>renal excretion of  flucytosine decreased and cellular uptake increased by amphotericin (toxicity possibly increased)</td><td>Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</td></tr><tr><td><a href="41001i821.htm">Cytarabine</a></td><td>plasma concentration of  flucytosine possibly reduced by cytarabine </td><td></td></tr></tbody></table><p><b>Griseofulvin</b> belongs to
      <b>Antifungals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i20.htm">Alcohol</a></td><td> griseofulvin possibly enhances effects of alcohol </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td> griseofulvin possibly reduces plasma concentration of ciclosporin </td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> griseofulvin reduces anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td>anecdotal reports of contraceptive failure and menstrual irregularities when  griseofulvin given with oestrogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>absorption of  griseofulvin reduced by phenobarbital (reduced effect)</td><td></td></tr><tr><td><a href="41001i664.htm">Progestogens</a></td><td>anecdotal reports of contraceptive failure and menstrual irregularities when  griseofulvin given with progestogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr></tbody></table><p><b>Terbinafine</b> belongs to
      <b>Antifungals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td> terbinafine possibly increases plasma concentration of tricyclics </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td> terbinafine possibly reduces plasma concentration of ciclosporin </td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  terbinafine increased by cimetidine </td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td>occasional reports of breakthrough bleeding when  terbinafine given with oestrogens (when used for contraception)</td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i664.htm">Progestogens</a></td><td>occasional reports of breakthrough bleeding when  terbinafine given with progestogens (when used for contraception)</td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  terbinafine reduced by rifampicin </b></td><td></td></tr></tbody></table><p><b>Antifungals, Imidazole</b> belongs to
      <b>Antifungals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>











<tr><td><a href="41001i290.htm">Amphotericin</a></td><td> imidazoles possibly antagonise effects of amphotericin </td><td>Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  imidazoles advised by manufacturer of artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  imidazoles given with atorvastatin </td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  imidazoles given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b> imidazoles possibly inhibit metabolism of mizolastine (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td>anecdotal reports of contraceptive failure when  imidazoles given with oestrogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  imidazoles given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> imidazoles possibly increase plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i231.htm">Reboxetine</a></td><td class="cBV"><b>avoidance of  imidazoles advised by manufacturer of reboxetine </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td> imidazoles possibly increase plasma concentration of saquinavir </td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> imidazoles possibly increase plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr></tbody></table><p><b>Ketoconazole</b> belongs to
      <b>Antifungals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


























































































<tr><td><a href="41001i30.htm">Alfuzosin</a></td><td> ketoconazole possibly increases plasma concentration of alfuzosin </td><td></td></tr><tr><td><a href="41001i1099.htm">Aliskiren</a></td><td> ketoconazole increases plasma concentration of aliskiren </td><td></td></tr><tr><td><a href="41001i1124.htm">Alitretinoin</a></td><td> ketoconazole increases plasma concentration of alitretinoin </td><td></td></tr><tr><td><a href="41001i925.htm">Almotriptan</a></td><td> ketoconazole increases plasma concentration of almotriptan (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i406.htm">Alprazolam</a></td><td> ketoconazole increases plasma concentration of alprazolam </td><td></td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  ketoconazole reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i342.htm">Antimuscarinics</a></td><td>absorption of  ketoconazole reduced by antimuscarinics </td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i1217.htm">Apixaban</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of apixaban—manufacturer of apixaban advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1010.htm">Aprepitant</a></td><td> ketoconazole increases plasma concentration of aprepitant </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> ketoconazole inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of boceprevir </b></td><td></td></tr><tr><td><a href="41001i1116.htm">Bortezomib</a></td><td> ketoconazole increases plasma concentration of bortezomib </td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td> ketoconazole increases plasma concentration of bosentan </td><td></td></tr><tr><td><a href="41001i496.htm">Budesonide</a></td><td> ketoconazole increases plasma concentration of <i>inhaled</i> and <i>oral</i> budesonide </td><td></td></tr><tr><td><a href="41001i87.htm">Buprenorphine</a></td><td class="cBV"><b> ketoconazole inhibits metabolism of buprenorphine (reduce dose of buprenorphine)</b></td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  ketoconazole advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i469.htm">Calcium-channel Blockers (dihydropyridines)</a></td><td> ketoconazole possibly inhibits metabolism of dihydropyridines (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td> ketoconazole possibly increases plasma concentration of carbamazepine </td><td></td></tr><tr><td><a href="41001i1043.htm">Ciclesonide</a></td><td> ketoconazole increases plasma concentration of active metabolite of ciclesonide </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> ketoconazole inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i940.htm">Cilostazol</a></td><td> ketoconazole increases plasma concentration of cilostazol (consider reducing dose of cilostazol)</td><td></td></tr><tr><td><a href="41001i1022.htm">Cinacalcet</a></td><td> ketoconazole inhibits metabolism of cinacalcet (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> ketoconazole possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> ketoconazole possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i484.htm">Corticosteroids</a></td><td> ketoconazole possibly inhibits metabolism of corticosteroids </td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> ketoconazole enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1120.htm">Dabigatran Etexilate</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of dabigatran etexilate—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td> ketoconazole increases plasma concentration of darifenacin—avoid concomitant use</td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td>plasma concentration of both drugs increased when  ketoconazole given with darunavir </td><td></td></tr><tr><td><a href="41001i1077.htm">Dasatinib</a></td><td> ketoconazole possibly increases plasma concentration of dasatinib </td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  ketoconazole given with disopyramide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i516.htm">Docetaxel</a></td><td><i>in vitro</i> studies suggest a possible interaction between  ketoconazole and docetaxel (consult docetaxel product literature)</td><td></td></tr><tr><td><a href="41001i553.htm">Domperidone</a></td><td class="cBV"><b>manufacturer of  ketoconazole advises avoid concomitant use with domperidone (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of dronedarone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i963.htm">Eletriptan</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td> ketoconazole inhibits metabolism of erlotinib (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of everolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i471.htm">Felodipine</a></td><td class="cBV"><b> ketoconazole inhibits metabolism of felodipine (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i1119.htm">Fesoterodine</a></td><td>manufacturer of fesoterodine advises dose reduction when  ketoconazole given with fesoterodine—consult fesoterodine product literature</td><td></td></tr><tr><td><a href="41001i1202.htm">Fingolimod</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of fingolimod </b></td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td>plasma concentration of  ketoconazole increased by fosamprenavir (also plasma concentration of fosamprenavir possibly increased)</td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i915.htm">Galantamine</a></td><td> ketoconazole increases plasma concentration of galantamine </td><td></td></tr><tr><td><a href="41001i743.htm">Histamine H<sub>2</sub>-antagonists</a></td><td>absorption of  ketoconazole reduced by histamine H<sub>2</sub>-antagonists </td><td></td></tr><tr><td><a href="41001i933.htm">Imatinib</a></td><td> ketoconazole increases plasma concentration of imatinib </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of indinavir (consider reducing dose of indinavir)</b></td><td></td></tr><tr><td><a href="41001i1006.htm">Irinotecan</a></td><td class="cBV"><b> ketoconazole reduces plasma concentration of  irinotecan (but concentration of active metabolite of irinotecan increased)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i165.htm">Isoniazid</a></td><td>plasma concentration of  ketoconazole possibly reduced by isoniazid </td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of ivabradine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1092.htm">Lanthanum</a></td><td>absorption of   ketoconazole possibly reduced by lanthanum (give at least 2 hours apart)</td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of lapatinib—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i846.htm">Lercanidipine</a></td><td>avoidance of  ketoconazole advised by manufacturer of lercanidipine </td><td></td></tr><tr><td><a href="41001i309.htm">Loratadine</a></td><td>manufacturer of loratadine advises  ketoconazole possibly increases plasma concentration of loratadine </td><td></td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of maraviroc (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i337.htm">Mefloquine</a></td><td> ketoconazole increases plasma concentration of mefloquine </td><td></td></tr><tr><td><a href="41001i492.htm">Methylprednisolone</a></td><td> ketoconazole inhibits the metabolism of methylprednisolone </td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of midazolam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i823.htm">Mirtazapine</a></td><td> ketoconazole increases plasma concentration of mirtazapine </td><td></td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b> ketoconazole inhibits metabolism of mizolastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i968.htm">Mometasone</a></td><td> ketoconazole increases plasma concentration of <i>inhaled</i> mometasone </td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td class="cBV"><b>plasma concentration of  ketoconazole reduced by nevirapine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1118.htm">Nilotinib</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of nilotinib—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1093.htm">Paricalcitol</a></td><td> ketoconazole possibly increases plasma concentration of paricalcitol </td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  ketoconazole advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>plasma concentration of  ketoconazole reduced by phenytoin </b></td><td></td></tr><tr><td><a href="41001i751.htm">Proton Pump Inhibitors</a></td><td>absorption of  ketoconazole reduced by proton pump inhibitors </td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of ranolazine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>metabolism of  ketoconazole accelerated by rifampicin (reduced plasma concentration), also plasma concentration of rifampicin may be reduced by ketoconazole</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>combination of  ketoconazole with ritonavir may increase plasma concentration of either drug (or both)</b></td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of rivaroxaban—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1155.htm">Rupatadine</a></td><td> ketoconazole increases plasma concentration of rupatadine </td><td></td></tr><tr><td><a href="41001i727.htm">Salmeterol</a></td><td> ketoconazole inhibits metabolism of salmeterol (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td> ketoconazole increases plasma concentration of saquinavir </td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td> ketoconazole increases plasma concentration of sildenafil—reduce initial dose of sildenafil</td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  ketoconazole given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of sirolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1020.htm">Solifenacin</a></td><td> ketoconazole increases plasma concentration of solifenacin </td><td></td></tr><tr><td><a href="41001i755.htm">Sucralfate</a></td><td>absorption of  ketoconazole reduced by sucralfate </td><td></td></tr><tr><td><a href="41001i1075.htm">Sunitinib</a></td><td> ketoconazole inhibits metabolism of sunitinib (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of tacrolimus (consider reducing dose of tacrolimus)</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of tadalafil—manufacturer of tadalafil advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of both drugs possibly increased when  ketoconazole given with telaprevir (increased risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>avoidance of concomitant  ketoconazole in severe renal and hepatic impairment advised by manufacturer of telithromycin </b></td><td></td></tr><tr><td><a href="41001i1137.htm">Temsirolimus</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of active metabolite of temsirolimus—avoid concomitant use</b></td><td>The main active metabolite of temsirolimus is sirolimus—<i>see also</i> interactions of sirolimus and consult product literature</td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b> ketoconazole possibly increases plasma concentration of theophylline </b></td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of ticagrelor—manufacturer of ticagrelor advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td>avoidance of  ketoconazole advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i1158.htm">Tolvaptan</a></td><td> ketoconazole increases plasma concentration of tolvaptan </td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of vardenafil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1181.htm">Vinflunine</a></td><td class="cBV"><b> ketoconazole increases plasma concentration of vinflunine—manufacturer of vinflunine advises avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Miconazole</b> belongs to
      <b>Antifungals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>









<tr><td><a href="41001i277.htm">Carbamazepine</a></td><td> miconazole possibly increases plasma concentration of carbamazepine </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> miconazole possibly inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> miconazole enhances anticoagulant effect of coumarins (miconazole oral gel and possibly vaginal and topical formulations absorbed)</b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i271.htm">Gliclazide</a></td><td class="cBV"><b> miconazole enhances hypoglycaemic effect of gliclazide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i272.htm">Glipizide</a></td><td class="cBV"><b> miconazole enhances hypoglycaemic effect of glipizide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> miconazole enhances anticonvulsant effect of phenytoin (plasma concentration of phenytoin increased)</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  miconazole given with simvastatin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> miconazole increases plasma concentration of sirolimus </b></td><td></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td class="cBV"><b> miconazole increases plasma concentration of sulfonylureas </b></td><td></td></tr></tbody></table><p><b>Antifungals, Triazole</b> belongs to
      <b>Antifungals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>










<tr><td><a href="41001i290.htm">Amphotericin</a></td><td> triazoles possibly antagonise effects of amphotericin </td><td>Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  triazoles advised by manufacturer of artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  triazoles given with atorvastatin </td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  triazoles given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i95.htm">Fentanyl</a></td><td class="cBV"><b> triazoles possibly increase plasma concentration of fentanyl </b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  triazoles given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> triazoles possibly increase plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i231.htm">Reboxetine</a></td><td class="cBV"><b>avoidance of  triazoles advised by manufacturer of reboxetine </b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> triazoles possibly increase plasma concentration of rifabutin (increased risk of uveitis—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td> triazoles possibly increase plasma concentration of saquinavir </td><td></td></tr></tbody></table><p><b>Posaconazole</b> belongs to
      <b>Antifungals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


























<tr><td><a href="41001i1217.htm">Apixaban</a></td><td>avoidance of  posaconazole advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b> posaconazole increases plasma concentration of atazanavir </b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  posaconazole given with atorvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  posaconazole possibly reduced by carbamazepine </b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> posaconazole inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td class="cBV"><b>plasma concentration of  posaconazole reduced by cimetidine </b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>avoidance of  posaconazole advised by manufacturer of dronedarone </b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b>plasma concentration of  posaconazole reduced by efavirenz </b></td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> posaconazole possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i272.htm">Glipizide</a></td><td> posaconazole possibly enhances hypoglycaemic effect of glipizide </td><td></td></tr><tr><td><a href="41001i743.htm">Histamine H<sub>2</sub>-antagonists</a></td><td>manufacturer of  posaconazole advises avoid concomitant use with histamine H<sub>2</sub>-antagonists (plasma concentration of posaconazole possibly reduced)</td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  posaconazole advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> posaconazole increases plasma concentration of midazolam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>plasma concentration of  posaconazole possibly reduced by phenobarbital </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>plasma concentration of  posaconazole reduced by phenytoin </b></td><td></td></tr><tr><td><a href="41001i751.htm">Proton Pump Inhibitors</a></td><td>manufacturer of  posaconazole advises avoid concomitant use with proton pump inhibitors (plasma concentration of posaconazole possibly reduced)</td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> posaconazole possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> posaconazole increases plasma concentration of rifabutin (also plasma concentration of posaconazole reduced)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  posaconazole reduced by rifampicin </b></td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td>avoidance of  posaconazole advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  posaconazole given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td> posaconazole possibly increases plasma concentration of sirolimus </td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> posaconazole increases plasma concentration of tacrolimus (consider reducing dose of tacrolimus)</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of  posaconazole possibly increased by telaprevir (increased risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1002.htm">Vinblastine</a></td><td class="cBV"><b> posaconazole possibly inhibits metabolism of vinblastine (increased risk of neurotoxicity)</b></td><td></td></tr><tr><td><a href="41001i815.htm">Vincristine</a></td><td class="cBV"><b> posaconazole possibly inhibits metabolism of vincristine (increased risk of neurotoxicity)</b></td><td></td></tr></tbody></table><p><b>Voriconazole</b> belongs to
      <b>Antifungals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




































<tr><td><a href="41001i86.htm">Alfentanil</a></td><td class="cBV"><b> voriconazole increases plasma concentration of alfentanil (consider reducing dose of alfentanil)</b></td><td></td></tr><tr><td><a href="41001i1217.htm">Apixaban</a></td><td>avoidance of  voriconazole advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  voriconazole advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  voriconazole possibly reduced by carbamazepine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> voriconazole inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> voriconazole possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> voriconazole enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i412.htm">Diazepam</a></td><td class="cBV"><b> voriconazole increases plasma concentration of diazepam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i64.htm">Diclofenac</a></td><td> voriconazole increases plasma concentration of diclofenac </td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>avoidance of  voriconazole advised by manufacturer of dronedarone </b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b>plasma concentration of  voriconazole reduced by efavirenz , also plasma concentration of efavirenz increased (increase voriconazole dose and reduce efavirenz dose)</b></td><td></td></tr><tr><td><a href="41001i914.htm">Esomeprazole</a></td><td> voriconazole possibly increases plasma concentration of esomeprazole </td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> voriconazole possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i783.htm">Ibuprofen</a></td><td> voriconazole increases plasma concentration of ibuprofen </td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  voriconazole advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td class="cBV"><b> voriconazole increases plasma concentration of methadone (consider reducing dose of methadone)</b></td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> voriconazole increases plasma concentration of midazolam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i1118.htm">Nilotinib</a></td><td class="cBV"><b>avoidance of  voriconazole advised by manufacturer of nilotinib </b></td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td>plasma concentration of  voriconazole increased by oestrogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td> voriconazole increases plasma concentration of omeprazole (consider reducing dose of omeprazole)</td><td></td></tr><tr><td><a href="41001i901.htm">Oxycodone</a></td><td class="cBV"><b> voriconazole increases plasma concentration of oxycodone </b></td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  voriconazole advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>plasma concentration of  voriconazole possibly reduced by phenobarbital—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> voriconazole increases plasma concentration of phenytoin , also phenytoin reduces plasma concentration of voriconazole (increase dose of voriconazole and also monitor for phenytoin toxicity)</b></td><td></td></tr><tr><td><a href="41001i664.htm">Progestogens</a></td><td>plasma concentration of  voriconazole possibly increased by progestogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> voriconazole possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> voriconazole increases plasma concentration of rifabutin , also rifabutin reduces plasma concentration of voriconazole (increase dose of voriconazole and also monitor for rifabutin toxicity)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  voriconazole reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  voriconazole reduced by ritonavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td>avoidance of  voriconazole advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td>possible increased risk of myopathy when  voriconazole given with simvastatin </td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> voriconazole increases plasma concentration of sirolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  voriconazole reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td> voriconazole possibly increases plasma concentration of sulfonylureas </td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> voriconazole increases plasma concentration of tacrolimus (consider reducing dose of tacrolimus)</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of  voriconazole possibly affected by telaprevir (possible increased risk of ventricular arrhythmias)</b></td><td></td></tr></tbody></table><p><b>Fluconazole</b> belongs to
      <b>Antifungals</b>
          and has the following interaction information:
        </p><div>In general, fluconazole interactions relate to multiple-dose treatment</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





























<tr><td><a href="41001i86.htm">Alfentanil</a></td><td> fluconazole inhibits metabolism of alfentanil (risk of prolonged or delayed respiratory depression)</td><td></td></tr><tr><td><a href="41001i242.htm">Amitriptyline</a></td><td> fluconazole possibly increases plasma concentration of amitriptyline </td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td class="cBV"><b> fluconazole possibly increases plasma concentration of bosentan—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td> fluconazole possibly increases plasma concentration of carbamazepine </td><td></td></tr><tr><td><a href="41001i898.htm">Celecoxib</a></td><td> fluconazole increases plasma concentration of celecoxib (halve dose of celecoxib)</td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> fluconazole inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> fluconazole possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> fluconazole enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i412.htm">Diazepam</a></td><td class="cBV"><b> fluconazole increases plasma concentration of diazepam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td> fluconazole increases plasma concentration of eplerenone (reduce dose of eplerenone)</td><td></td></tr><tr><td><a href="41001i69.htm">Flurbiprofen</a></td><td> fluconazole increases plasma concentration of flurbiprofen </td><td></td></tr><tr><td><a href="41001i603.htm">Fluvastatin</a></td><td> fluconazole increases plasma concentration of fluvastatin </td><td></td></tr><tr><td><a href="41001i530.htm">Hydrochlorothiazide</a></td><td>plasma concentration of  fluconazole increased by hydrochlorothiazide </td><td></td></tr><tr><td><a href="41001i783.htm">Ibuprofen</a></td><td> fluconazole increases plasma concentration of ibuprofen </td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td> fluconazole increases plasma concentration of ivabradine—reduce initial dose of ivabradine</td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> fluconazole increases plasma concentration of midazolam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i920.htm">Nateglinide</a></td><td> fluconazole possibly enhances hypoglycaemic effect of nateglinide </td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td class="cBV"><b> fluconazole increases plasma concentration of nevirapine </b></td><td></td></tr><tr><td><a href="41001i961.htm">Parecoxib</a></td><td> fluconazole increases plasma concentration of parecoxib (reduce dose of parecoxib)</td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> fluconazole increases plasma concentration of phenytoin (consider reducing dose of phenytoin)</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> fluconazole increases plasma concentration of rifabutin (increased risk of uveitis—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>metabolism of  fluconazole accelerated by rifampicin (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td> fluconazole increases plasma concentration of ritonavir </td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  fluconazole given with simvastatin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td class="cBV"><b> fluconazole increases plasma concentration of sulfonylureas </b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> fluconazole increases plasma concentration of tacrolimus (consider reducing dose of tacrolimus)</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b> fluconazole possibly increases plasma concentration of theophylline </b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td> fluconazole increases plasma concentration of tipranavir </td><td></td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td class="cBV"><b> fluconazole increases plasma concentration of zidovudine (increased risk of toxicity)</b></td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr></tbody></table><p><b>Itraconazole</b> belongs to
      <b>Antifungals</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





































































<tr><td><a href="41001i86.htm">Alfentanil</a></td><td> itraconazole possibly inhibits metabolism of alfentanil </td><td></td></tr><tr><td><a href="41001i1099.htm">Aliskiren</a></td><td class="cBV"><b> itraconazole increases plasma concentration of aliskiren—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i406.htm">Alprazolam</a></td><td> itraconazole increases plasma concentration of alprazolam </td><td></td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  itraconazole reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i1217.htm">Apixaban</a></td><td>avoidance of  itraconazole advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> itraconazole possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  itraconazole given with atorvastatin </b></td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td> itraconazole possibly increases plasma concentration of bosentan </td><td></td></tr><tr><td><a href="41001i496.htm">Budesonide</a></td><td> itraconazole increases plasma concentration of <i>inhaled</i> budesonide </td><td></td></tr><tr><td><a href="41001i427.htm">Buspirone</a></td><td> itraconazole increases plasma concentration of buspirone (reduce dose of buspirone)</td><td></td></tr><tr><td><a href="41001i993.htm">Busulfan</a></td><td> itraconazole inhibits metabolism of busulfan (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  itraconazole advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td>negative inotropic effect possibly increased when  itraconazole given with calcium-channel blockers </td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i469.htm">Calcium-channel Blockers (dihydropyridines)</a></td><td> itraconazole possibly inhibits metabolism of dihydropyridines (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  itraconazole possibly reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> itraconazole inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td>plasma concentration of  itraconazole increased by clarithromycin </td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> itraconazole possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> itraconazole possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i484.htm">Corticosteroids</a></td><td> itraconazole possibly inhibits metabolism of corticosteroids </td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> itraconazole enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i502.htm">Cyclophosphamide</a></td><td> itraconazole possibly increases side-effects of cyclophosphamide </td><td></td></tr><tr><td><a href="41001i1120.htm">Dabigatran Etexilate</a></td><td class="cBV"><b> itraconazole possibly increases plasma concentration of dabigatran etexilate—manufacturer of dabigatran etexilate advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td>avoidance of  itraconazole advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td class="cBV"><b> itraconazole increases plasma concentration of digoxin </b></td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>manufacturer of  itraconazole advises avoid concomitant use with disopyramide </b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>avoidance of  itraconazole advised by manufacturer of dronedarone </b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  itraconazole reduced by efavirenz </td><td></td></tr><tr><td><a href="41001i963.htm">Eletriptan</a></td><td class="cBV"><b> itraconazole increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td class="cBV"><b> itraconazole increases plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> itraconazole possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i471.htm">Felodipine</a></td><td class="cBV"><b> itraconazole inhibits metabolism of felodipine (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i1119.htm">Fesoterodine</a></td><td>manufacturer of fesoterodine advises dose reduction when  itraconazole given with fesoterodine—consult fesoterodine product literature</td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td>plasma concentration of both drugs may increase when  itraconazole given with fosamprenavir </td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i1170.htm">Gefitinib</a></td><td> itraconazole increases plasma concentration of gefitinib </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td> itraconazole possibly increases plasma concentration of haloperidol </td><td></td></tr><tr><td><a href="41001i743.htm">Histamine H<sub>2</sub>-antagonists</a></td><td>absorption of  itraconazole reduced by histamine H<sub>2</sub>-antagonists </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b> itraconazole increases plasma concentration of indinavir (consider reducing dose of indinavir)</b></td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td class="cBV"><b> itraconazole possibly increases plasma concentration of ivabradine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  itraconazole advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i846.htm">Lercanidipine</a></td><td>avoidance of  itraconazole advised by manufacturer of lercanidipine </td><td></td></tr><tr><td><a href="41001i492.htm">Methylprednisolone</a></td><td> itraconazole possibly inhibits metabolism of methylprednisolone </td><td></td></tr><tr><td><a href="41001i1125.htm">Micafungin</a></td><td>plasma concentration of  itraconazole increased by micafungin (consider reducing dose of itraconazole)</td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> itraconazole increases plasma concentration of midazolam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b> itraconazole inhibits metabolism of mizolastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td>plasma concentration of  itraconazole possibly reduced by nevirapine—consider increasing dose of itraconazole</td><td></td></tr><tr><td><a href="41001i1118.htm">Nilotinib</a></td><td class="cBV"><b>avoidance of  itraconazole advised by manufacturer of nilotinib </b></td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  itraconazole advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  itraconazole possibly reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>plasma concentration of  itraconazole reduced by phenytoin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i751.htm">Proton Pump Inhibitors</a></td><td>absorption of  itraconazole reduced by proton pump inhibitors </td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> itraconazole possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i855.htm">Repaglinide</a></td><td> itraconazole possibly enhances hypoglycaemic effect of repaglinide </td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b>plasma concentration of  itraconazole reduced by rifabutin—manufacturer of itraconazole advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  itraconazole reduced by rifampicin—manufacturer of itraconazole advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>combination of  itraconazole with ritonavir may increase plasma concentration of either drug (or both)</b></td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td>avoidance of  itraconazole advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td> itraconazole increases plasma concentration of sildenafil—reduce initial dose of sildenafil</td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  itraconazole given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> itraconazole increases plasma concentration of sirolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1020.htm">Solifenacin</a></td><td> itraconazole increases plasma concentration of solifenacin </td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> itraconazole increases plasma concentration of tacrolimus (consider reducing dose of tacrolimus)</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td> itraconazole possibly increases plasma concentration of tadalafil </td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td>plasma concentration of  itraconazole possibly increased by telaprevir </td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td>avoidance of  itraconazole advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td class="cBV"><b> itraconazole possibly increases plasma concentration of vardenafil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i815.htm">Vincristine</a></td><td class="cBV"><b> itraconazole possibly inhibits metabolism of vincristine (increased risk of neurotoxicity)</b></td><td></td></tr><tr><td><a href="41001i1181.htm">Vinflunine</a></td><td class="cBV"><b> itraconazole possibly increases plasma concentration of vinflunine—manufacturer of vinflunine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1085.htm">Vinorelbine</a></td><td class="cBV"><b> itraconazole possibly inhibits metabolism of vinorelbine (increased risk of neurotoxicity)</b></td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i1125.htm" title="Micafungin">Micafungin</a></li><li><a href="41001i947.htm" title="Caspofungin">Caspofungin</a></li><li id="_41001i289"><a href="41001i289.htm" title="Antifungals, Polyene">Antifungals, Polyene</a></li><li><a href="41001i820.htm" title="Flucytosine">Flucytosine</a></li><li><a href="41001i291.htm" title="Griseofulvin">Griseofulvin</a></li><li><a href="41001i292.htm" title="Terbinafine">Terbinafine</a></li><li id="_41001i293"><a href="41001i293.htm" title="Antifungals, Imidazole">Antifungals, Imidazole</a></li><li id="_41001i300"><a href="41001i300.htm" title="Antifungals, Triazole">Antifungals, Triazole</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i287.htm">Previous: Vigabatrin</a> | <a class="top" href="41001i288.htm#">Top</a> | <a accesskey="]" href="41001i1125.htm">Next: Micafungin</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>